Literature DB >> 29696816

Deletion of Smad4 reduces hepatic inflammation and fibrogenesis during nonalcoholic steatohepatitis progression.

Geng Qin1, Guo Zhen Wang2, Dan Dan Guo3, Ru Xue Bai1, Miao Wang1, Shi Yu Du1.   

Abstract

OBJECTIVE: To explore the effects of mothers against decapentaplegic homolog family member 4 (Smad4) deletion on inflammation and fibrogenesis in nonalcoholic steatohepatitis (NASH).
METHODS: Biopsied liver samples from NASH patients and normal liver tissue samples from patients who had received liver resection for trauma were collected. Smad4Co/Co and wild-type (WT) mice were used to construct the NASH model using a high-fat diet (HFD) or methionine- and choline-deficient diet (MCD). HE staining and TUNEL assay were used to observe the pathological changes and cell apoptosis, respectively. Quantitative real-time polymerase chain reaction was used to detect the expression of inflammatory, fibrogenesis and apoptosis-related genes, and immunohistochemistry to determine the protein expression of SMAD4, MCP-1 and α-SMA.
RESULTS: SMAD4 protein expression significantly increased in NASH patients than in the control group. Compared with WT mice, HFD- and MCD-fed Smad4Co/Co mice showed decreased hepatic steatosis, inflammation, liver cell apoptosis and nonalcoholic fatty liver activity score, reduced plasma glucose, triglyceride, free fatty acids, alanine aminotransferase and aspartate aminotransferase levels but increased adiponectin. Moreover, Smad4Co/Co decreased the expression of inflammatory markers (TNF-α, MCP-1, IFN-γ), fibrogenetic markers (COL1A1, α-SMA and TGF-β1), lipogenic (Srebp1c, Fas and Acc) and proapoptotic genes (Bax and caspase-3), but increased the expression of β-oxidation (Ppar-α, Cpt1 and Aco) and antiapoptotic genes (Bcl-2).
CONCLUSION: Smad4 deletion may inhibit lipogenesis, stimulate β-oxidation, improve lipid metabolism and liver function, alleviate inflammation and fibrosis, and reduce cell apoptosis in NASH.
© 2018 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  SMAD4 protein; apoptosis; hepatic fibrogenesis; inflammation; nonalcoholic fatty liver disease

Mesh:

Substances:

Year:  2018        PMID: 29696816     DOI: 10.1111/1751-2980.12599

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  5 in total

1.  Characterization of regulatory transcriptional mechanisms in hepatocyte lipotoxicity.

Authors:  Joaquín Pérez-Schindler; Elyzabeth Vargas-Fernández; Bettina Karrer-Cardel; Danilo Ritz; Alexander Schmidt; Christoph Handschin
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

Review 2.  Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy.

Authors:  Jianan Zhao; Yiyang Hu; Jinghua Peng
Journal:  Cell Mol Biol Lett       Date:  2021-05-07       Impact factor: 5.787

3.  Hepatocyte-Specific Smad4 Deficiency Alleviates Liver Fibrosis via the p38/p65 Pathway.

Authors:  Miaomiao Wei; Xinlong Yan; Xin Xin; Haiqiang Chen; Lingling Hou; Jinhua Zhang
Journal:  Int J Mol Sci       Date:  2022-10-02       Impact factor: 6.208

4.  mRNA-miRNA-lncRNA Regulatory Network in Nonalcoholic Fatty Liver Disease.

Authors:  Marwa Matboli; Shaimaa H Gadallah; Wafaa M Rashed; Amany Helmy Hasanin; Nada Essawy; Hala M Ghanem; Sanaa Eissa
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

Review 5.  TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019.

Authors:  Bedair Dewidar; Christoph Meyer; Steven Dooley; And Nadja Meindl-Beinker
Journal:  Cells       Date:  2019-11-11       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.